This was a randomized safety/immunogenicity evaluation of PCV7 primary series at 3, 4, 5
months in healthy Chinese infants. Eight hundred subjects were randomized to Group 1 …

Background: 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in China
based on immunologic noninferiority to 7-valent PCV (PCV7). As part of the noninferiority …

Background: Meta-analyses enable summarization and interpretation of data across clinical
trials. When applied to safety data they allow for detection of rare events. Recently, a 13 …

Background The widespread use of pneumococcal conjugate vaccines (PCVs) has
significantly decreased pneumococcal disease worldwide. However, China has not adopted …

BACKGROUND: As 13-valent pneumococcal conjugate vaccine (PCV13) is introduced,
children who began vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) may …

Background: Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine
(PCV13) were compared with 7-valent pneumococcal conjugate vaccine (PCV7) in Chinese …

Immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines
(PCV13; PCV7) were compared in Taiwanese children. In this double-blind, multicenter …

Background: The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to
extend pneumococcal disease protection beyond 13-valent PCV (PCV13). Methods: This …

Background Pneumococcal disease (PD) remains a major health concern with considerable
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …

Background: The global distribution of pneumococcal disease and emergence of
nonvaccine pneumococcal serotypes prompted the development of a 13-valent …